Author Contributions: Dr Meyerhardt had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Meyerhardt, Saltz, Hu, Fuchs.
Acquisition of data: Meyerhardt, Niedzwiecki, Hollis, Saltz, Nelson, Whittom, Hantel, Thomas, Fuchs.
Analysis and interpretation of data: Meyerhardt, Niedzwiecki, Hollis, Saltz, Mayer, Fuchs.
Drafting of the manuscript: Meyerhardt, Niedzwiecki, Fuchs.
Critical revision of the manuscript for important intellectual content: Meyerhardt, Niedzwiecki, Hollis, Saltz, Hu, Mayer, Nelson, Whittom, Hantel, Thomas, Fuchs.
Statistical analysis: Meyerhardt, Niedzwiecki, Hollis, Hu, Fuchs.
Obtained funding: Meyerhardt, Mayer, Fuchs.
Administrative, technical, or material support: Meyerhardt, Saltz, Nelson, Fuchs.
Study supervision: Mayer, Fuchs.
Financial Disclosures: None reported.
Funding/Support: Cancer and Leukemia Group B (CALGB) 89803 was supported in part by grants from the National Cancer Institute (CA31946) to the CALGB (Richard L. Schilsky, MD, chairman) and to the CALGB Statistical Center (Stephen George, PhD; CA33601) as well as support from Pharmacia & Upjohn Company, now Pfizer Oncology. Dr Meyerhardt is supported in part by a K07 award from the National Cancer Institute (K07CA097992).
Role of the Sponsor: The sponsors did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Clinical Centers: Baptist Cancer Institute CCOP, Memphis, Tennessee (Lee S. Schwartzberg, MD; CA71323); Christiana Care Health Services Inc CCOP, Wilmington, Delaware (Stephen Grubbs, MD; CA45418); University of North Carolina, Chapel Hill (Thomas C. Shea, MD; CA47559); University of Chicago, Chicago, Illinois (Gini Fleming, MD; CA41287); Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, New Hampshire (Marc S. Ernstoff, MD; CA04326); Duke University Medical Center, Durham, North Carolina (Jeffrey Crawford, MD; CA47577); Dana-Farber Cancer Institute, Boston, Massachusetts (Eric P. Winer, MD; CA32291); Georgetown University Medical Center, Washington, DC (Edward Gelmann, MD; CA77597); Cancer Centers of the Carolinas, Greenville, South Carolina (Jeffrey K. Giguere, MD; CA29165); University of Illinois MBCCOP, Chicago (Lawrence E. Feldman, MD; CA74811); University of Iowa, Iowa City (Gerald Clamon, MD; CA47642); North Shore-Long Island Jewish Medical Center, Manhasset, New York (Daniel R Budman, MD; CA35279); University of Maryland Greenebaum Cancer Center, Baltimore (Martin Edelman, MD; CA31983); University of Massachusetts Medical School, Worcester (William V. Walsh, MD; CA37135); Massachusetts General Hospital, Boston (Michael L. Grossbard, MD; CA12449); Mount Sinai Medical Center, Miami, Florida (Rogerio Lilenbaum, MD; CA45564); University of Minnesota, Minneapolis (Bruce A Peterson, MD; CA16450); University of Missouri, Ellis Fischel Cancer Center, Columbia (Michael C Perry, MD; CA12046); Mount Sinai School of Medicine, New York, New York (Lewis R. Silverman, MD; CA04457); Memorial Sloan-Kettering Cancer Center, New York, New York (Clifford Hudis, MD; CA77651); University of Nebraska Medical Center, Omaha (Anne Kessinger, MD; CA77298); Long Island Jewish Medical Center, Lake Success, New York (Marc Citron, MD; CA11028); Ohio State University Medical Center, Columbus (Clara D. Bloomfield, MD; CA77658); Rhode Island Hospital, Providence (William Sikov, MD; CA08025); Roswell Park Cancer Institute, Buffalo, New York (Ellis Levine, MD; CA02599); Southeast Cancer Control Consortium Inc CCOP, Goldsboro, North Carolina (James N. Atkins, MD; CA45808); Southern Nevada Cancer Research Foundation CCOP, Las Vegas (John Ellerton, MD; CA35421); Syracuse Hematology-Oncology Assoc CCOP, Syracuse, New York (Jeffrey Kirshner, MD; CA45389); University of Tennessee, Memphis (Harvey B. Niell, MD; CA47555); University of California, San Diego (Joanne Mortimer, MD; CA11789); University of California, San Francisco (Alan P. Venook, MD; CA60138); Vermont Cancer Center, Burlington (Hyman B. Muss, MD; CA77406); Wake Forest University School of Medicine, Winston-Salem, North Carolina (David D. Hurd, MD; CA03927); Walter Reed Army Medical Center, Washington, DC (Thomas Reid, MD; CA26806); Washington University School of Medicine, St Louis, Missouri (Nancy Bartlett, MD; CA77440); and Weill Medical College of Cornell University, New York, New York (Scott Wadler, MD; CA07968).
Disclaimer: The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Additional Contributions: Walter Willett, MD, DrPH, at the Harvard School of Public Health, served as a nonpaid consultant for this study and provided expert comments on the analysis and the manuscript.